WebApr 14, 2024 · Abstract Background Prostate cancer (PCa) is a clinically heterogeneous disease. The creation of an expression-based subtyping model based on prostate … WebNow we're expanding that expertise by looking at specialties. After the publication of the first part in September, in which we awarded the best hospitals for cardiology, oncology and...
Celebration of Junior Investigators - DF/HCC
WebApr 10, 2024 · Tumor expression of prostate-specific membrane antigen (PSMA) is lost in 15–20% of men with castration-resistant prostate cancer (CRPC), yet the underlying … WebApr 10, 2024 · In a new study in the journal Nature Cancer, Dana-Farber Cancer Institute scientists shed new light on the mechanism that raises and lowers PSMA expression in prostate cancer cells. The findings may help physicians select PSMA-targeting therapies for specific patients, researchers say. Impact: schedule today at wimbledon
Counselling and Support for Cancer Patients - South Shore Health
WebApr 11, 2024 · In a recent study published in the journal Nature Cancer, scientists from the Dana-Farber Cancer Institute shed new light on the mechanism that raises and lowers … WebThe therapies may decrease mortality from prostate cancer if used when the localized disease is first diagnosed. ... The project was launched as a large-scale cohort research study by scientists at Dana-Farber/Brigham and Women’s Cancer Center and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center aimed at collecting as … WebApr 10, 2024 · In 15-20% of patients with castration-resistant prostate cancer, however, PSMA production stops at advanced stages of the disease. In a new study in the journal Nature Cancer, Dana-Farber Cancer Institute scientists shed new light on the mechanism that raises and lowers PSMA expression in prostate cancer cells. The findings may help … schedule today tnt